Printer Friendly

Scil Proteins in supply agreement with Actavis over Reteplease.

M2 PHARMA-January 17, 2012-Scil Proteins in supply agreement with Actavis over Reteplease(C)2012 M2 COMMUNICATIONS

17 January 2012 - German biopharmaceutical company Scil Proteins GmbH said on Tuesday that it had signed a supply agreement with generics drugs manufacturer Actavis for the future production of Reteplease.

Reteplase is a recombinant protein and the active ingredient in the medicinal product Rapilysin used for the thrombolytic treatment of myocardial infarction. In June 2008, Scil Proteins signed an agreement with Swiss Roche Holding AG (VTX:ROG) for process transfer and manufacture of Reteplase.

Actavis is the holder of the rights to the Reteplase production process and the distribution of Rapilysin in Europe and worldwide excluding the US and Canada.

((Comments on this story may be sent to

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 17, 2012
Previous Article:CrystalGenomics secures USD2.6m in strategic equity investment from KSLSF.
Next Article:MGB Biopharma selects Almac for contract manufacturing of antibacterial compound.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters